Expert Interview
Exploring the Potential of Brensocatib in Bronchiectasis: A Deep Dive into Insmed's ASPEN Study
Ticker(s): INSMInstitution: Columbia University Medical Center
- Professor of Medicine at CUMC & Director of the Columbia University Gunnar Esiason Adult Cystic Fibrosis (CF) Program and the Asthma Research Program.
- Manages 100 patients with non-CF bronchiectasis and 175 patients with cystic fibrosis.
- Serves as Principal Investigator for numerous research projects in the areas of cystic fibrosis and asthma.
Can you explain how brensocatib's inhibition of dipeptidyl peptidase 1 (DPP1) impacts the progression of bronchiectasis, and what makes this approach unique compared to existing treatments?
The ASPEN study's primary endpoint is the rate of pulmonary exacerbations over a 52-week treatment period. Why is this a critical measure for bronchiectasis, and what impact could brensocatib have on this aspect of the disease?
Based on the ASPEN study design, what are the key safety parameters being monitored for brensocatib, and how might these findings influence its clinical use?
The study involves two different dosages of brensocatib (10 mg and 25 mg). What insights are you hoping to gain from comparing these dosages in terms of efficacy and safety?
With brensocatib being a potential long-term treatment option, what are the considerations or concerns in managing patients over an extended period?
Assuming positive results from the ASPEN study, how do you foresee brensocatib changing the landscape of bronchiectasis treatment and management?
Added By: catalin_adminConsidering the symptoms of bronchiectasis, such as chronic cough and excessive sputum production, how might brensocatib improve the quality of life for patients?
Added By: catalin_adminInsmed is also exploring brensocatib for other neutrophil-driven inflammatory diseases. Can you discuss the potential broader implications of this research?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
